{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T21:16:36Z","timestamp":1780953396864,"version":"3.54.1"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Blood\u2013brain barrier (BBB) disruption after endothelial damage is a crucial part of radiation-induced brain necrosis (RN), but little is known of BBB disruption quantification and its role in the evaluation of therapeutic effect and prognosis for drug treatment. In this retrospective study, BBB repair by bevacizumab and corticosteroid and the correlation between BBB permeability and treatment response and relapse were evaluated by dynamic contrast-enhanced MRI (DCE-MRI).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Forty-one patients with RN after radiotherapy for nasopharyngeal carcinoma (NPC) (28 treated with bevacizumab and 13 with corticosteroid), 12 patients with no RN after NPC radiotherapy, and 12 patients with no radiotherapy history were included as RN, non-RN, and normal groups, respectively. DCE-MRI assessed BBB permeability in white matter of bilateral temporal lobe. DCE parameters were compared at baseline among the three groups. DCE parameters after treatment were compared and correlated with RN volume decrease, neurological improvement, and relapse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The extent of BBB leakage at baseline increased from the normal group and non-RN group and to RN necrosis lesions, especially <jats:italic>K<\/jats:italic><jats:sup>trans<\/jats:sup> (Kruskal\u2013Wallis test, <jats:italic>P<\/jats:italic>\u00a0&amp;lt;\u00a00.001). In the RN group, bevacizumab-induced <jats:italic>K<\/jats:italic><jats:sup>trans<\/jats:sup> and <jats:italic>v<\/jats:italic><jats:sub>e<\/jats:sub> decrease in radiation necrosis lesions (both <jats:italic>P<\/jats:italic>\u00a0&amp;lt;\u00a00.001), while corticosteroid showed no obvious effect on BBB. The treatment response rate of bevacizumab was significantly higher than that of corticosteroid [30\/34 (88.2%) <jats:italic>vs<\/jats:italic>. 10\/22 (45.4%), <jats:italic>P<\/jats:italic>\u00a0&amp;lt;\u00a00.001]. Spearman analysis showed baseline <jats:italic>K<\/jats:italic><jats:sup>trans<\/jats:sup>, <jats:italic>K<\/jats:italic><jats:sub>ep<\/jats:sub>, and <jats:italic>v<\/jats:italic><jats:sub>p<\/jats:sub> positively correlated with RN volume decrease and improvement of cognition and quality of life in bevacizumab treatment. After a 6-month follow-up for treatment response cases, the relapse rate of bevacizumab and corticosteroid was 10\/30 (33.3%) and 2\/9 (22.2%), respectively, with no statistical difference. Post-bevacizumab <jats:italic>K<\/jats:italic><jats:sup>trans<\/jats:sup> level predicted relapse in 6\u00a0months with AUC 0.745 (<jats:italic>P<\/jats:italic>\u00a0&amp;lt;\u00a00.05, 95% CI 0.546\u20130.943, sensitivity\u00a0=\u00a00.800, specificity\u00a0=\u00a00.631).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Bevacizumab improved BBB leakage in RN necrosis. DCE parameters may be useful to predict therapeutic effect and relapse after bevacizumab.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.720417","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T22:27:32Z","timestamp":1633559252000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Blood\u2013Brain Barrier Repair of Bevacizumab and Corticosteroid as Prediction of Clinical Improvement and Relapse Risk in Radiation-Induced Brain Necrosis: A Retrospective Observational Study"],"prefix":"10.3389","volume":"11","author":[{"given":"Ruiqi","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Rong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongteng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyu","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2013.05.015","article-title":"Challenges With the Diagnosis and Treatment of Cerebral Radiation Necrosis","volume":"87","author":"Chao","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B2","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11912-019-0818-y","article-title":"Cerebral Radiation Necrosis: Incidence, Pathogenesis, Diagnostic Challenges, and Future Opportunities","volume":"21","author":"Ali","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms161126068","article-title":"Molecular, Cellular and Functional Effects of Radiation-Induced Brain Injury: A Review","volume":"16","author":"Balentova","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1667\/RR3117","article-title":"Early Radiation-Induced Endothelial Cell Loss and Blood-Spinal Cord Barrier Breakdown in the Rat Spinal Cord","volume":"161","author":"Li","year":"2004","journal-title":"Radiat Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.06.043","article-title":"Effects of Fractionated Radiation on the Brain Vasculature in a Murine Model: Blood-Brain Barrier Permeability, Astrocyte Proliferation, and Ultrastructural Changes","volume":"66","author":"Yuan","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-199906000-00006","article-title":"Vascular Endothelial Growth Factor (VEGF) Modulates Vascular Permeability and Inflammation in Rat Brain","volume":"58","author":"Proescholdt","year":"1999","journal-title":"J Neuropathol Exp Neurol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.2176\/nmc.ra.2014-0188","article-title":"Pathophysiology, Diagnosis, and Treatment of Radiation Necrosis in the Brain","volume":"55","author":"Miyatake","year":"2015","journal-title":"Neurol Medico-Chirurgica"},{"key":"B8","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten Years of Anti-Vascular Endothelial Growth Factor Therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-13-1941","article-title":"Anti-VEGF Antibodies Mitigate the Development of Radiation Necrosis in Mouse Brain","volume":"20","author":"Jiang","year":"2014","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12943-019-0950-1","article-title":"Bevacizumab Treatment for Radiation Brain Necrosis: Mechanism, Efficacy and Issues","volume":"18","author":"Zhuang","year":"2019","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/not085","article-title":"Bevacizumab as a Treatment for Radiation Necrosis of Brain Metastases Post Stereotactic Radiosurgery","volume":"15","author":"Boothe","year":"2013","journal-title":"Neuro Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2018.04.068","article-title":"Bevacizumab Monotherapy Reduces Radiation-Induced Brain Necrosis in Nasopharyngeal Carcinoma Patients: A Randomized Controlled Trial","volume":"101","author":"Xu","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2017.11.023","article-title":"Clinical Variables for Prediction of the Therapeutic Effects of Bevacizumab Monotherapy in Nasopharyngeal Carcinoma Patients With Radiation-Induced Brain Necrosis","volume":"100","author":"Li","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2009.12.061","article-title":"Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous System","volume":"79","author":"Levin","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.08.092","article-title":"Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Biomarker for the Pharmacological Response of PTK787\/ZK 222584, an Inhibitor of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinases, in Patients With Advanced Colorectal Cancer and Liver Metastases: Results From Two Phase I Studies","volume":"21","author":"Morgan","year":"2003","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2012.2","article-title":"Dynamic Contrast-Enhanced MRI in Clinical Trials of Antivascular Therapies","volume":"9","author":"O\u2019Connor","year":"2012","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neuron.2014.12.032","article-title":"Blood-Brain Barrier Breakdown in the Aging Human Hippocampus","volume":"85","author":"Montagne","year":"2015","journal-title":"Neuron"},{"key":"B18","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00401-016-1570-0","article-title":"Brain Imaging of Neurovascular Dysfunction in Alzheimer\u2019s Disease","volume":"131","author":"Montagne","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2019.01.013","article-title":"Quantifying Blood-Brain Barrier Leakage in Small Vessel Disease: Review and Consensus Recommendations","volume":"15","author":"Thrippleton","year":"2019","journal-title":"Alzheimers Dement"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2247-3","article-title":"APOE4 Leads to Blood-Brain Barrier Dysfunction Predicting Cognitive Decline","volume":"581","author":"Montagne","year":"2020","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12916-016-0725-0","article-title":"Neuroimaging in Vascular Cognitive Impairment: A State-of-the-Art Review","volume":"14","author":"Heiss","year":"2016","journal-title":"BMC Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1259\/bjro.20180023","article-title":"Differentiating the Lymph Node Metastasis of Breast Cancer Through Dynamic Contrast-Enhanced Magnetic Resonance Imaging","volume":"1","author":"Dong","year":"2019","journal-title":"BJR Open"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.20699","article-title":"Measurement of Single Kidney Function Using Dynamic Contrast-Enhanced MRI: Comparison of Two Models in Human Subjects","volume":"24","author":"Buckley","year":"2006","journal-title":"J Magn Reson Imaging JMRI"},{"key":"B24","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/jmri.1880070113","article-title":"Modeling Tracer Kinetics in Dynamic Gd-DTPA MR Imaging","volume":"7","author":"Tofts","year":"1997","journal-title":"J Magn Reson Imaging"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1522-2586(199909)10:3<223::AID-JMRI2>3.0.CO;2-S","article-title":"Estimating Kinetic Parameters From Dynamic Contrast-Enhanced T(1)-Weighted MRI of a Diffusable Tracer: Standardized Quantities and Symbols","volume":"10","author":"Tofts","year":"1999","journal-title":"J Magn Resonance Imaging JMRI"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-08-1420","article-title":"Dynamic Contrast-Enhanced Magnetic Resonance Imaging As a Biomarker for Prediction of Radiation-Induced Neurocognitive Dysfunction","volume":"15","author":"Cao","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool for Mild Cognitive Impairment","volume":"53","author":"Nasreddine","year":"2005","journal-title":"J Am Geriatrics Soc"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(02)04578-9","article-title":"Evaluation of the LENT-SOMA Scales for the Prospective Assessment of Treatment Morbidity in Cervical Carcinoma","volume":"56","author":"Routledge","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1017\/s0033291798006667","article-title":"Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. The WHOQOL Group","volume":"28","year":"1998","journal-title":"Psychol Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1471-2105-12-77","article-title":"pROC: An Open-Source Package for R and S+ to Analyze and Compare ROC Curves","volume":"12","author":"Robin","year":"2011","journal-title":"BMC Bioinf"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in Cancer Treatment: A Review of 15 Years of Clinical Experience and Future Outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat Rev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2009.110","article-title":"Targeting Angiogenesis: Progress With Anti-VEGF Treatment With Large Molecules","volume":"6","author":"Grothey","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/nbm.2940","article-title":"Classic Models for Dynamic Contrast-Enhanced MRI","volume":"26","author":"Sourbron","year":"2013","journal-title":"NMR BioMed"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-020-07296-5","article-title":"Dynamic Contrast-Enhanced Magnetic Resonance Imaging Biomarkers Predict Chemotherapeutic Responses and Survival in Primary Central-Nervous-System Lymphoma","volume":"31","author":"Fu","year":"2021","journal-title":"Eur Radiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1002\/mrm.1910170208","article-title":"Measurement of the Blood-Brain Barrier Permeability and Leakage Space Using Dynamic MR Imaging. 1. Fundamental Concepts","volume":"17","author":"Tofts","year":"1991","journal-title":"Magn Reson Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1921","article-title":"Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Assessing Tumor Vascularity and Vascular Effects of Targeted Therapies in Renal Cell Carcinoma","volume":"13","author":"Rosen","year":"2007","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01198-1","article-title":"Impaired Meningeal Lymphatic Drainage in Patients With Idiopathic Parkinson\u2019s Disease","volume":"27","author":"Ding","year":"2021","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.692051","article-title":"Impaired Meningeal Lymphatic Flow in NMOSD Patients With Acute Attack","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.720417\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T22:27:35Z","timestamp":1633559255000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.720417\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":38,"alternative-id":["10.3389\/fonc.2021.720417"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.720417","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"article-number":"720417"}}